A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome - Test2 - elhamkhani - TriplyDB

A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome

A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome

http://www.wikidata.org/entity/Q36996583

about

Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder Characterizing autism spectrum disorders by key biochemical pathways.Dysregulation and restoration of translational homeostasis in fragile X syndrome A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders Emerging pharmacologic treatment options for fragile X syndrome Fragile X-associated tremor/ataxia syndrome.Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.Fragile X syndrome The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back Review of targeted treatments in fragile X syndrome The neurobiology of the Prader-Willi phenotype of fragile X syndrome Fragile X mental retardation protein: A paradigm for translational control by RNA-binding proteins From FMRP function to potential therapies for fragile X syndrome.Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model.Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study.Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder.Fragile X syndrome: a review of clinical and molecular diagnoses.Fragile X Syndrome: Prevalence, Treatment, and Prevention in China Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.Fragile X targeted pharmacotherapy: lessons learned and future directions.Effects of a social stimulus on gene expression in a mouse model of fragile X syndrome Dysregulated nitric oxide signaling as a candidate mechanism of fragile X syndrome and other neuropsychiatric disorders.Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells.A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial Modulation of the GABAergic pathway for the treatment of fragile X syndrome.Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.Improving Treatment Trial Outcomes for Rett Syndrome: The Development of Rett-specific Anchors for the Clinical Global Impression Scale Identification of a male with fragile X syndrome through newborn screening TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME A Spoken-Language Intervention for School-Aged Boys With Fragile X Syndrome Transient ECM protease activity promotes synaptic plasticity.A male with cooccurrence of down syndrome and fragile x syndrome.Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models.The challenges of clinical trials in fragile X syndrome.New innovations: therapeutic opportunities for intellectual disabilities.Development of mavoglurant and its potential for the treatment of fragile X syndrome.

P2860

Q26781265-27DE339E-FE9B-490F-B30C-EF17371071AC Q26781645-CA6F013E-24A1-4731-94CF-5063483BC959 Q26782616-9193B287-2AC8-4F5B-A105-C8E93F829691 Q26797397-2E859A55-1283-4D38-BA8C-3A13494F6D49 Q26829152-A092B11F-5D84-4B49-AA11-B9064DCEA427 Q26852667-2517AE65-6E66-4672-8DBA-EC91F512B10E Q26866506-98DD8C07-79EC-4C18-A938-E52C1D10DD22 Q26995168-AA9B9582-DED4-449C-B5AE-8147C13A292D Q26998975-D0F175C6-0636-46AD-A752-45533782B95E Q27023257-9BD019B0-6A5E-489C-AE8C-73A244B66D35 Q27337360-D26BABD4-0DC7-46AD-967B-F12B0C3A274D Q28077180-10709F7A-196F-400A-8CF7-B58DE631F27B Q28078294-A4B1183B-A573-42B4-B15F-4BB97FEF88E8 Q28086823-0F1BAB36-B719-4A6B-BE9F-A58AA9112D5B Q30410502-4ED19F87-6FCF-41B6-8EA8-B366B20CE91E Q30418368-2AC1D22F-B028-44E7-AB1C-880568AF656B Q31043571-1E71A487-5AA9-48EC-8F8C-F0476B2BA397 Q33565886-364AD94E-C622-46C0-A591-D3DC13E17ED6 Q33576328-1477D609-9832-47BA-A503-A3715D845F86 Q33766106-C19B5B24-E073-48E5-9978-08844CFE502F Q33785978-FC493148-F399-49C6-905E-A4F18CAF21BF Q33785983-425F1D51-2B98-4D26-8A2D-44ECF89073BF Q33827442-6689B4EE-CD37-4073-819A-672CFD4F31D8 Q33929361-87617A23-2DE5-45D9-B9AA-FA885B3417C9 Q33935973-8490199E-F40C-45D7-A757-53493523D03F Q33942366-72C8206B-8653-42AA-932D-9CB5CD9EABB4 Q34207747-85B68239-54AA-49A3-A3C1-0665413535ED Q34230612-6B8EF74A-E366-4AA0-A01E-1227A972E080 Q34487591-424E3275-B8AD-4413-B92F-86371DDD6366 Q34959355-0ED4E6D9-3976-4993-B402-4B065C002040 Q36176918-63D7E07C-82C9-4414-888A-75A394295066 Q36322068-E0DB3061-9547-4911-8185-5C2F5B2989DE Q36399716-A1678EE0-F4B7-4E8D-BEDD-1EDFB12DC23E Q36847586-BE412D76-3DA6-4A37-A02F-4A0981F315C5 Q36990679-EC16E72F-56C6-4039-A33D-F61E82FB830B Q37191302-1C6F06BF-B38A-49C5-80A7-46FF6CA03DD9 Q37564195-CD76075E-4FBA-44D2-951F-C9C2A9E532F0 Q37598441-5A509A95-4DF1-4040-BBCC-9E09EAD7F16A Q38137883-37069E3B-21F4-48B6-A209-E867AC2D523C Q38164021-44BCF687-7010-4D0A-A56E-F141600E3BD2

P2860

A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome

http://www.wikidata.org/entity/Q36996583

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

A randomized double-blind, pla ...... scents with fragile x syndrome

@en

type

label

A randomized double-blind, pla ...... scents with fragile x syndrome

@en

prefLabel

A randomized double-blind, pla ...... scents with fragile x syndrome

@en

P1433

Q36996583-10D9E60F-41A1-49A9-A8F2-53419098BE1A

P1476

Q36996583-0B9CB030-D5CB-44E4-A2F0-CA6FE07C5F6E

P2093

Q36996583-1DCF2118-696F-4AEC-9277-A7A30E8AA231

Q36996583-254E7989-AFF3-40F8-A033-5A663FD55F7D

Q36996583-345B0AB0-7DE4-40BB-8F62-F6618056CCA1

Q36996583-3E4608B0-E657-4D23-8747-1DD8B91A8517

Q36996583-43A0D972-7BC5-432F-9BBC-3842F454AF06

Q36996583-49C5DD76-131C-45F5-9281-8138133E15F1

Q36996583-7A82F970-0079-4D69-B181-124298110943

Q36996583-7E79637D-D817-438A-8867-EED5FA17EAF7

Q36996583-B88F76BA-AB6B-4534-8D51-0B8E4D3328C0

Q36996583-B9494EB1-6B9D-45DF-BA5E-3929AD92EBA0

P2860

Q36996583-0864C4D9-6195-491E-8CE0-002C7FB15183

Q36996583-0B733F9E-CAFB-4E24-9DD1-66EF2FE8899B

Q36996583-1333F4E6-45FD-4A27-BEC7-8F8489D5CB50

Q36996583-17727989-95BC-4ADC-BD65-4223E522CDAF

Q36996583-1A3DCB36-3EBC-4C2B-9AFF-E840A1312816

Q36996583-1B8D8C55-17ED-476A-9E1A-CD6FBABE663C

Q36996583-1C5CC558-57BA-4D85-9DC3-ADE8EFA3D361

Q36996583-20F39C7E-FE20-4A4B-8363-6C85F74BACA3

Q36996583-27B92797-D039-4781-BBA7-6825AAC33F7D

Q36996583-3BAE3673-0468-45A5-8A73-67D7A4E020C1

P304

Q36996583-4EE46217-9B48-4665-B18C-0BA87258E66E

P31

Q36996583-5701F328-AC6D-4FAE-8B6A-B326BFE43FE4

P356

Q36996583-00B02154-D41F-45E4-BE8B-739F15537D09

P433

Q36996583-40973992-E768-4120-B9FA-C59FE1B22218

P478

Q36996583-BF2F08FA-243B-446D-876B-FCD16E248602

P50

Q36996583-15F9D16E-51AF-4816-8F67-8BBB22224F80

P577

Q36996583-61B7C83E-AB17-49C3-92C7-2144467A77A9

P698

Q36996583-8559B994-419B-4EE9-901B-CFEBF4560A0E

P921

Q36996583-22920487-F4F2-4799-A56A-B502A8E2F718

Q36996583-295F1F3C-6178-43EF-8CAA-877C028ABF4D

P932

Q36996583-6F00DC70-D7BC-447B-9EAB-0561FDE0D5F0

P356

DBP.0B013E318287CD17

P1433

Journal of Developmental and Behavioral Pediatrics

P1476

A randomized double-blind, pla ...... scents with fragile x syndrome

@en

P2093

Danh V Nguyen

http://www.w3.org/2001/XMLSchema#string

David Hessl

http://www.w3.org/2001/XMLSchema#string

Flora Tassone

http://www.w3.org/2001/XMLSchema#string

Jonathan Polussa

http://www.w3.org/2001/XMLSchema#string

Mary Jacena S Leigh

http://www.w3.org/2001/XMLSchema#string

Paul Doucet

http://www.w3.org/2001/XMLSchema#string

Randi J Hagerman

http://www.w3.org/2001/XMLSchema#string

Susan M Rivera

http://www.w3.org/2001/XMLSchema#string

Tasleem Chechi

http://www.w3.org/2001/XMLSchema#string

Tri I Winarni

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism-based approaches to treating fragile X

FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

Fragile X syndrome and targeted treatment trials.

How matrix metalloproteinases regulate cell behavior

Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures

Open-label add-on treatment trial of minocycline in fragile X syndrome.

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.

Prospects for minocycline neuroprotection.

P304

147-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/DBP.0B013E318287CD17

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Schneider

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23572165

http://www.w3.org/2001/XMLSchema#string

P921

P932

3706260

http://www.w3.org/2001/XMLSchema#string